2026-04-29T01:00:10Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/185802024-02-27T14:57:49Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Arriola, Edurne
author
González-Cao, María
author
Domine, Manuel
author
De Castro, Javier
author
Cobo, Manuel
author
Bernabé, Reyes
author
Navarro, Alejandro
author
Sullivan, Ivana
author
Trigo, José Manuel
author
Mosquera, Joaquín
author
Crama, Leonardo
author
Isla, Dolores
2024-02-27T14:57:49Z
2024-02-27T14:57:49Z
2022-01-15
http://hdl.handle.net/10668/21742
http://hdl.handle.net/20.500.12105/18580
35032007
10.1007/s40487-021-00182-0
2366-1089
Oncology and therapy
The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. Two independent reviewers extracted relevant data according to PRISMA guidelines and assessed the risk of bias using the Cochrane Collaboration's risk-of-bias tool. Meta-analysis was conducted using random-effects models to calculate an average effect size for overall survival (OS), progression-free survival (PFS), and safety outcomes in the overall populations and clinically relevant subgroups. A literature search of PubMed and Embase was performed. Six randomized controlled clinical trials (IMpower133, CHECKMATE-451, CASPIAN, KEYNOTE-604, and phase II and III ipilimumab plus CT trials) with a total of 3757 patients were included. Compared with CT alone, ICIs plus CT showed a favourable effect on OS (hazard ratio [HR] 0.85; 95% confidence intervals [CI] 0.79-0.96) and PFS (HR 0.78; 95% CI 0.72-0.83) but a non-significant increase in the risk of experiencing any adverse event (relative risk, 1.05; 95% CI 0.99-1.11). The estimated HR for OS favoured ICI combinations in all planned subgroups according to age ( Combining anti-programmed cell death ligand 1 antibodies with platinum/etoposide is a superior therapeutic approach compared to CT alone for the first-line treatment of patients with ES-SCLC.
eng
Anti-PD-1/PD-L1 antibodies
Chemotherapy
Immunotherapy
Meta-analysis
Small cell lung carcinoma
Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
research article